Bicara Therapeutics Inc. Common Stock Total Liabilities

Latest as of June 2026: $43.48 Million USD

Bicara Therapeutics Inc. Common Stock total liabilities. Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has total liabilities worth $43.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bicara Therapeutics Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Bicara Therapeutics Inc. Common Stock (2022–2025)

Total liabilities of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. This chart illustrates how Bicara Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore Bicara Therapeutics Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.

Bicara Therapeutics Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Hg Technologies Co Ltd SHE:300847	China	CN¥140.67 Million
Huarong Chemical Co. Ltd. SHE:301256	China	CN¥646.41 Million
Khang Dien House Trading and Investment JSC VN:KDH	Vietnam	₫18.34 Trillion
Suzhou Etron Technologies Co Ltd SHG:603380	China	CN¥1.06 Billion
Anhui Province Natural Gas Development Co Ltd SHG:603689	China	CN¥3.61 Billion
V2 Retail Limited NSE:V2RETAIL	India	Rs15.20 Billion
Ningbo Techmation Co Ltd SHG:603015	China	CN¥653.36 Million
CK Power Public Company Limited BK:CKP	Thailand	฿34.71 Billion

Liability Composition Analysis (2022–2025)

This chart breaks down Bicara Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Bicara Therapeutics Inc. Common Stock.

Liquidity & Leverage Metrics

Bicara Therapeutics Inc. Common Stock Total Liabilities Ratios Explained

Bicara Therapeutics Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	11.59	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.09	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.08	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bicara Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bicara Therapeutics Inc. Common Stock (2022–2025)

The table below shows the annual total liabilities of Bicara Therapeutics Inc. Common Stock from 2022 to 2025.

Year	Total Liabilities	Change
2025-12-31	$29.54 Million	-61.79%
2024-12-31	$77.32 Million	+399.68%
2023-12-31	$15.47 Million	-35.47%
2022-12-31	$23.98 Million	--

About Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX USA Biotechnology

Market Cap

$588.28 Million

Market Cap Rank

#11102 Global

#2909 in USA

Share Price

$8.89

Change (1 day)

-0.78%

52-Week Range

$7.93 - $30.40

All Time High

$30.40